GUILFORD, Conn., Jan 13, 2025 — InveniAI LLC, a global leader in the application of artificial intelligence (AI), machine learning (ML), and generative AI tools to revolutionize drug discovery and development, today announced several transformative milestones as part of its continued commitment to revolutionizing the drug development process. To mark this next chapter of innovation, the company has launched a wholly owned subsidiary, AlphaMeld® Corporation, a name that reflects its mission to meld advanced artificial intelligence, machine learning, and generative AI with domain expertise to identify "alpha signals" of innovation for the development of impactful therapeutic solutions.
The company's new milestones highlight recent innovation and expansion including advanced small molecule design capabilities, biologics design capabilities (including antibody and antibody-drug conjugate design), next-generation interactive ChatAlphaMeld™, and a comprehensive AI-powered obesity disease model.
AlphaMeld Corporation now offers advanced capabilities in designing small molecules, enabling the platform to rapidly prototype and optimize therapeutic candidates, accelerating program timelines. By leveraging this capability, AlphaMeld Corporation has successfully progressed several candidates from target identification to pre-IND within just 6-9 months.
The company also offers biologics design capabilities, including the design of novel antibodies and selection of candidates for antibody-drug conjugates (ADCs). This module integrates AI-driven design and advanced analytics to enhance both the precision and efficacy of biologics, which are emerging as a cornerstone across many therapeutic areas.
The launch of next-gen ChatAlphaMeld as a dedicated biopharma agent leveraging large language models (LLMs) sets a new benchmark for interactivity and usability in AI platforms for both expert and non-expert users. This tool allows researchers to seamlessly interact with the AlphaMeld technology platform and its comprehensive datasets and algorithms, making hypothesis generation and validation more intuitive than ever before.
AlphaMeld Corporation has also unveiled a comprehensive AI-powered obesity disease model, identifying novel biological pathways and therapeutic targets to address the unmet needs of the existing landscape.
"With our rebranding to AlphaMeld Corporation, we are cementing our position at the forefront of AI-driven drug discovery," said Krishnan Nandabalan, Ph.D., President, Chairman, and CEO of AlphaMeld Corporation. "Our innovative platforms and expanded capabilities are poised to address some of the most complex challenges in medicine today."